Gefitinib

Title	Average Rating
Lessons learned in the development of targeted therapy for malignant gliomas	50.00%
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations.	40.00%

Calendar